# U.S. Department of Veterans Affairs

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/us-department-of-veterans-affairs
Canonical HTML page: https://getbiobrief.com/entity/us-department-of-veterans-affairs

## Timeline

- **2026-04-30**: Expansion Target — Goal to reach 130 active sales territories by fiscal year-end
- **2026-03-17**: Earnings Release — Announced 63% revenue growth and VA hospital network access
- **2026-01-31**: Q3 Fiscal End — Closed third quarter with 100 active sales territories
- **2025-12-01**: Equity Offering — Completed capital raise to bolster cash position to $291M

## Recent coverage (2 stories)

### 37.7% Heart Event Drop with COVID Vaccine Opens New Indication Potential
2026-06-28 15:23:49 · Sentiment: Positive · Impact: 7/10 · Sources: 4

The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
Full story: https://getbiobrief.com/story/covid-vaccine-cardiovascular-indication-bio

### Kestra Medical Surges 63% on Assure Growth and Strategic VA Expansion
2026-03-18 00:40:35 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator. The company significantly expanded its market access through a new U.S. Department of Veterans Affairs contract and improved Medicaid coverage in Florida.
Full story: https://getbiobrief.com/story/kestra-medical-kmts-q3-2026-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.